Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations

Prostate Cancer and Prostatic Diseases, Published online: 19 November 2022; doi:10.1038/s41391-022-00612-8Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations

Source: Prostate Cancer and Prostatic Diseases - November 19, 2022 Category: Urology & Nephrology Authors: Corbin J. Eule Thomas W. Flaig Katy Wong Ryon Graf Elaine T. Lam Source Type: research